COVID-19 Vaccine AstraZeneca EU Webcast

02 mrt
2 maart 2021 19:00 – 20:15Toevoegen aan kalender 2021-03-02 18:00:00 2021-03-02 19:15:00 Title Description Location Domus Medica Europe/Brussels public
Andere organisatie

0000 Bij u thuis

bekijk in Google Maps
Inschrijven voor deze activiteit

Safety and efficacy of COVID-19 Vaccine AstraZeneca: a vaccine approved for SARS-CoV-2 in Europe


  • Welcome and introduction - Iskra Reic (AstraZeneca) | Tobias Welte (Germany)
  • The fight against SARS-CoV-2: the vaccine landscape in Europe - Tobias Welte (Germany)
  • Conducting clinical trials during a pandemic: the COVID-19 Vaccine AstraZeneca story - Hugo Gomes da Silva (AstraZeneca)
  • Safety, efficacy and immunogenicity of COVID-19 Vaccine AstraZeneca - Hugo Gomes da Silva (AstraZeneca)
  • Vaccine rollout: key learnings, best practice and future perspectives - Kirsty Le Doare (UK)
  • Audience Q&A - All faculty
  • Meeting close - Tobias Welte (Germany)


Please use this opportunity to submit your questions to the faculty. All questions submitted during the registration will be collated, and we will aim to answer as many as possible during the live Q&A session


Tobias Welte is Professor of Pulmonary Medicine and Head of the Department of Pulmonary and Infectious Diseases at Hannover University School of Medicine. He received his doctorate in respiratory medicine from Hannover University in 1994 and his habilitation in 2000. He was previously Professor of Pneumology and Intensive Care Medicine, and a Specialist in infectious diseases at the University of Magdeburg. He is currently an executive board member of the German Center for Lung Research, internal advisor for the German Center for Infection Research and a member of the review panel of the German Research Foundation (DFG). In addition, he is the Chairman of the German Foundation for Community-acquired Pneumonia (CAPNETZ) and an advisory board member of the German Competence Network Sepsis (SepNet). Professor Welte is also a Past President of the European Respiratory Society.

Kirsty Le Doare is Professor of Vaccinology and Immunology at St George’s, University of London. She conducts research on Maternal Vaccines, Paediatric Infection and Immunity in both the UK and Uganda. Her work is focused on harnessing basic pathophysiology and immunity to improve vaccines and prevention strategies, coupled with clinical vaccine studies. As well as holding a Chair in Vaccinology and Immunology, she is a Principal Scientist at The Medical Research Council / Uganda Virus Research Institute. Here she is developing a maternal vaccine platform and surveillance of pregnancy outcomes in a large urban cohort. She is also jointly appointed to Public Health England as a Principal Scientist with the Pathogen Immunity Group, Porton Down, and was awarded a UK Research and Innovation (UKRI) Future Leaders Fellowship in 2019.

Hugo Gomes da Silva is the Global Medical Head for Vaccines and Infectious Diseases at AstraZeneca. Hugo holds a medical degree from the Faculty of Medical Sciences, University of Lisbon and a postgraduate degree in business and administration. Before joining the pharmaceutical industry, he worked as a Medical Doctor in an Internal Medicine / Infectious Diseases ward and as an Assistant Professor of Molecular, Cellular and Developmental Biology at the University of Lisbon, focusing his research on virology, immunology, genetic testing and, particularly, the host response to HIV infection. Hugo has over 20 years of research and development experience, and has worked in global, regional and country roles in different organisations. He was the medical lead for the development of several infectious disease drugs and vaccines, such as the integrase strand transfer inhibitors for HIV, the inactivated H1N1 pandemic vaccine in 2009 and the current WHO-recommended seasonal quadrivalent flu vaccine. Hugo led several post-approval studies associated with the H1N1 pandemic, and developed a pandemic readiness plan in partnership with governments around the world.

This promotional meeting has been organised and funded by AstraZeneca